nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—GNRHR—GPCRs, Other—HRH4—stomach cancer	0.00731	0.0533	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—KISS1R—stomach cancer	0.00568	0.0414	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1R—stomach cancer	0.00508	0.037	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—AGTR2—stomach cancer	0.00501	0.0365	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—F2R—stomach cancer	0.0042	0.0306	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.00376	0.0274	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—KISS1—stomach cancer	0.00366	0.0267	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—stomach cancer	0.00327	0.0239	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—RGS2—stomach cancer	0.00315	0.0229	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GAST—stomach cancer	0.00315	0.0229	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—ADRB2—stomach cancer	0.0031	0.0226	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—KISS1R—stomach cancer	0.00286	0.0209	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RGS2—stomach cancer	0.00282	0.0205	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—stomach cancer	0.00282	0.0205	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.00272	0.0198	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.00242	0.0177	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—F2R—stomach cancer	0.00236	0.0172	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—ANXA1—stomach cancer	0.00222	0.0162	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—stomach cancer	0.00211	0.0154	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—HRH4—stomach cancer	0.00207	0.0151	CbGpPWpGaD
Nafarelin—Bladder pain—Epirubicin—stomach cancer	0.00202	0.00234	CcSEcCtD
Nafarelin—Cystitis noninfective—Doxorubicin—stomach cancer	0.00202	0.00234	CcSEcCtD
Nafarelin—Cystitis—Doxorubicin—stomach cancer	0.002	0.00231	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—stomach cancer	0.00198	0.0145	CbGpPWpGaD
Nafarelin—Sweating increased—Capecitabine—stomach cancer	0.00196	0.00227	CcSEcCtD
Nafarelin—Weight increased—Docetaxel—stomach cancer	0.00189	0.00219	CcSEcCtD
Nafarelin—Vertigo—Irinotecan—stomach cancer	0.00188	0.00218	CcSEcCtD
Nafarelin—Dysuria—Capecitabine—stomach cancer	0.00188	0.00218	CcSEcCtD
Nafarelin—Weight decreased—Docetaxel—stomach cancer	0.00188	0.00218	CcSEcCtD
Nafarelin—Rash maculo-papular—Doxorubicin—stomach cancer	0.00188	0.00218	CcSEcCtD
Nafarelin—Bladder pain—Doxorubicin—stomach cancer	0.00187	0.00217	CcSEcCtD
Nafarelin—Neoplasm—Doxorubicin—stomach cancer	0.00187	0.00217	CcSEcCtD
Nafarelin—Hepatic function abnormal—Epirubicin—stomach cancer	0.00186	0.00215	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—KISS1—stomach cancer	0.00185	0.0135	CbGpPWpGaD
Nafarelin—Weight increased—Capecitabine—stomach cancer	0.00183	0.00212	CcSEcCtD
Nafarelin—Acute coronary syndrome—Docetaxel—stomach cancer	0.00183	0.00212	CcSEcCtD
Nafarelin—Weight decreased—Capecitabine—stomach cancer	0.00182	0.00211	CcSEcCtD
Nafarelin—Myocardial infarction—Docetaxel—stomach cancer	0.00182	0.0021	CcSEcCtD
Nafarelin—Conjunctivitis—Docetaxel—stomach cancer	0.0018	0.00209	CcSEcCtD
Nafarelin—Eye pain—Epirubicin—stomach cancer	0.0018	0.00208	CcSEcCtD
Nafarelin—Depression—Capecitabine—stomach cancer	0.00179	0.00207	CcSEcCtD
Nafarelin—Acute coronary syndrome—Capecitabine—stomach cancer	0.00177	0.00205	CcSEcCtD
Nafarelin—Cerebrovascular accident—Methotrexate—stomach cancer	0.00177	0.00205	CcSEcCtD
Nafarelin—Myocardial infarction—Capecitabine—stomach cancer	0.00176	0.00204	CcSEcCtD
Nafarelin—Epistaxis—Docetaxel—stomach cancer	0.00175	0.00203	CcSEcCtD
Nafarelin—Conjunctivitis—Capecitabine—stomach cancer	0.00174	0.00202	CcSEcCtD
Nafarelin—Convulsion—Fluorouracil—stomach cancer	0.00174	0.00201	CcSEcCtD
Nafarelin—Hot flush—Epirubicin—stomach cancer	0.00173	0.00201	CcSEcCtD
Nafarelin—Increased appetite—Epirubicin—stomach cancer	0.00173	0.002	CcSEcCtD
Nafarelin—Menopausal symptoms—Epirubicin—stomach cancer	0.00172	0.00199	CcSEcCtD
Nafarelin—Hepatic function abnormal—Doxorubicin—stomach cancer	0.00172	0.00199	CcSEcCtD
Nafarelin—Oedema—Irinotecan—stomach cancer	0.00171	0.00198	CcSEcCtD
Nafarelin—Myalgia—Fluorouracil—stomach cancer	0.00171	0.00198	CcSEcCtD
Nafarelin—Chest pain—Fluorouracil—stomach cancer	0.00171	0.00198	CcSEcCtD
Nafarelin—Epistaxis—Capecitabine—stomach cancer	0.00169	0.00196	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—stomach cancer	0.00169	0.0123	CbGpPWpGaD
Nafarelin—Shock—Irinotecan—stomach cancer	0.00168	0.00195	CcSEcCtD
Nafarelin—Rhinitis—Docetaxel—stomach cancer	0.00167	0.00193	CcSEcCtD
Nafarelin—Eye pain—Doxorubicin—stomach cancer	0.00166	0.00193	CcSEcCtD
Nafarelin—Cerebrovascular accident—Epirubicin—stomach cancer	0.00165	0.00192	CcSEcCtD
Nafarelin—Hyperhidrosis—Irinotecan—stomach cancer	0.00165	0.00192	CcSEcCtD
Nafarelin—Mood swings—Methotrexate—stomach cancer	0.00164	0.0019	CcSEcCtD
Nafarelin—Oedema—Fluorouracil—stomach cancer	0.00164	0.0019	CcSEcCtD
Nafarelin—Anorexia—Irinotecan—stomach cancer	0.00163	0.00189	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—KISS1R—stomach cancer	0.00162	0.0118	CbGpPWpGaD
Nafarelin—Rhinitis—Capecitabine—stomach cancer	0.00161	0.00187	CcSEcCtD
Nafarelin—Hot flush—Doxorubicin—stomach cancer	0.0016	0.00186	CcSEcCtD
Nafarelin—Increased appetite—Doxorubicin—stomach cancer	0.0016	0.00185	CcSEcCtD
Nafarelin—Affect lability—Epirubicin—stomach cancer	0.0016	0.00185	CcSEcCtD
Nafarelin—Menopausal symptoms—Doxorubicin—stomach cancer	0.00159	0.00184	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	0.00158	0.0115	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	0.00156	0.0114	CbGpPWpGaD
Nafarelin—Anorexia—Fluorouracil—stomach cancer	0.00156	0.00181	CcSEcCtD
Nafarelin—Insomnia—Irinotecan—stomach cancer	0.00155	0.00179	CcSEcCtD
Nafarelin—Mood swings—Epirubicin—stomach cancer	0.00154	0.00178	CcSEcCtD
Nafarelin—Paraesthesia—Irinotecan—stomach cancer	0.00153	0.00178	CcSEcCtD
Nafarelin—Cerebrovascular accident—Doxorubicin—stomach cancer	0.00153	0.00177	CcSEcCtD
Nafarelin—Dyspnoea—Irinotecan—stomach cancer	0.00152	0.00177	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	0.00152	0.0111	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Fluorouracil—stomach cancer	0.00149	0.00173	CcSEcCtD
Nafarelin—Dry skin—Epirubicin—stomach cancer	0.00149	0.00172	CcSEcCtD
Nafarelin—Decreased appetite—Irinotecan—stomach cancer	0.00149	0.00172	CcSEcCtD
Nafarelin—Insomnia—Fluorouracil—stomach cancer	0.00148	0.00172	CcSEcCtD
Nafarelin—Affect lability—Doxorubicin—stomach cancer	0.00148	0.00171	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—KISS1R—stomach cancer	0.00147	0.0107	CbGpPWpGaD
Nafarelin—Paraesthesia—Fluorouracil—stomach cancer	0.00147	0.0017	CcSEcCtD
Nafarelin—Alopecia—Docetaxel—stomach cancer	0.00147	0.0017	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	0.00147	0.0107	CbGpPWpGaD
Nafarelin—Constipation—Irinotecan—stomach cancer	0.00146	0.00169	CcSEcCtD
Nafarelin—Dyspnoea—Fluorouracil—stomach cancer	0.00146	0.00169	CcSEcCtD
Nafarelin—Mental disorder—Docetaxel—stomach cancer	0.00146	0.00169	CcSEcCtD
Nafarelin—Malnutrition—Docetaxel—stomach cancer	0.00145	0.00168	CcSEcCtD
Nafarelin—Gastritis—Epirubicin—stomach cancer	0.00144	0.00166	CcSEcCtD
Nafarelin—Muscular weakness—Epirubicin—stomach cancer	0.00143	0.00166	CcSEcCtD
Nafarelin—Decreased appetite—Fluorouracil—stomach cancer	0.00142	0.00165	CcSEcCtD
Nafarelin—Alopecia—Capecitabine—stomach cancer	0.00142	0.00165	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	0.00142	0.0104	CbGpPWpGaD
Nafarelin—Mood swings—Doxorubicin—stomach cancer	0.00142	0.00165	CcSEcCtD
Nafarelin—Dysgeusia—Docetaxel—stomach cancer	0.00142	0.00164	CcSEcCtD
Nafarelin—Abdominal distension—Epirubicin—stomach cancer	0.00141	0.00164	CcSEcCtD
Nafarelin—Mental disorder—Capecitabine—stomach cancer	0.00141	0.00164	CcSEcCtD
Nafarelin—Malnutrition—Capecitabine—stomach cancer	0.0014	0.00162	CcSEcCtD
Nafarelin—Dysuria—Methotrexate—stomach cancer	0.0014	0.00162	CcSEcCtD
Nafarelin—Dry skin—Doxorubicin—stomach cancer	0.00138	0.00159	CcSEcCtD
Nafarelin—Dysgeusia—Capecitabine—stomach cancer	0.00137	0.00159	CcSEcCtD
Nafarelin—Depression—Methotrexate—stomach cancer	0.00133	0.00154	CcSEcCtD
Nafarelin—Gastritis—Doxorubicin—stomach cancer	0.00133	0.00154	CcSEcCtD
Nafarelin—Muscular weakness—Doxorubicin—stomach cancer	0.00132	0.00153	CcSEcCtD
Nafarelin—Dysuria—Epirubicin—stomach cancer	0.00131	0.00152	CcSEcCtD
Nafarelin—Abdominal distension—Doxorubicin—stomach cancer	0.00131	0.00151	CcSEcCtD
Nafarelin—Urticaria—Fluorouracil—stomach cancer	0.0013	0.00151	CcSEcCtD
Nafarelin—Conjunctivitis—Methotrexate—stomach cancer	0.0013	0.0015	CcSEcCtD
Nafarelin—Palpitations—Docetaxel—stomach cancer	0.00128	0.00148	CcSEcCtD
Nafarelin—Weight increased—Epirubicin—stomach cancer	0.00128	0.00148	CcSEcCtD
Nafarelin—Weight decreased—Epirubicin—stomach cancer	0.00127	0.00147	CcSEcCtD
Nafarelin—Epistaxis—Methotrexate—stomach cancer	0.00126	0.00146	CcSEcCtD
Nafarelin—Vertigo—Capecitabine—stomach cancer	0.00126	0.00146	CcSEcCtD
Nafarelin—Convulsion—Docetaxel—stomach cancer	0.00125	0.00145	CcSEcCtD
Nafarelin—Palpitations—Capecitabine—stomach cancer	0.00124	0.00144	CcSEcCtD
Nafarelin—Chest pain—Docetaxel—stomach cancer	0.00123	0.00143	CcSEcCtD
Nafarelin—Arthralgia—Docetaxel—stomach cancer	0.00123	0.00143	CcSEcCtD
Nafarelin—Myalgia—Docetaxel—stomach cancer	0.00123	0.00143	CcSEcCtD
Nafarelin—Asthenia—Irinotecan—stomach cancer	0.00123	0.00142	CcSEcCtD
Nafarelin—Conjunctivitis—Epirubicin—stomach cancer	0.00121	0.00141	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—stomach cancer	0.00121	0.00141	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—AGTR2—stomach cancer	0.0012	0.00877	CbGpPWpGaD
Nafarelin—Myalgia—Capecitabine—stomach cancer	0.00119	0.00138	CcSEcCtD
Nafarelin—Chest pain—Capecitabine—stomach cancer	0.00119	0.00138	CcSEcCtD
Nafarelin—Arthralgia—Capecitabine—stomach cancer	0.00119	0.00138	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—F2R—stomach cancer	0.00119	0.00867	CbGpPWpGaD
Nafarelin—Oedema—Docetaxel—stomach cancer	0.00118	0.00137	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—stomach cancer	0.00118	0.00137	CcSEcCtD
Nafarelin—Epistaxis—Epirubicin—stomach cancer	0.00118	0.00137	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—stomach cancer	0.00117	0.00136	CcSEcCtD
Nafarelin—Sinusitis—Epirubicin—stomach cancer	0.00117	0.00136	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—HRH4—stomach cancer	0.00117	0.00853	CbGpPWpGaD
Nafarelin—Diarrhoea—Irinotecan—stomach cancer	0.00117	0.00136	CcSEcCtD
Nafarelin—Shock—Docetaxel—stomach cancer	0.00116	0.00135	CcSEcCtD
Nafarelin—Pruritus—Fluorouracil—stomach cancer	0.00116	0.00134	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—HTR1A—stomach cancer	0.00116	0.00844	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	0.00115	0.0084	CbGpPWpGaD
Nafarelin—Oedema—Capecitabine—stomach cancer	0.00114	0.00133	CcSEcCtD
Nafarelin—Dizziness—Irinotecan—stomach cancer	0.00113	0.00131	CcSEcCtD
Nafarelin—Anorexia—Docetaxel—stomach cancer	0.00113	0.00131	CcSEcCtD
Nafarelin—Shock—Capecitabine—stomach cancer	0.00113	0.0013	CcSEcCtD
Nafarelin—Rhinitis—Epirubicin—stomach cancer	0.00112	0.0013	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—stomach cancer	0.00112	0.0013	CcSEcCtD
Nafarelin—Diarrhoea—Fluorouracil—stomach cancer	0.00112	0.0013	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—ANXA1—stomach cancer	0.00112	0.00815	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Capecitabine—stomach cancer	0.00111	0.00128	CcSEcCtD
Nafarelin—Epistaxis—Doxorubicin—stomach cancer	0.00109	0.00126	CcSEcCtD
Nafarelin—Anorexia—Capecitabine—stomach cancer	0.00109	0.00126	CcSEcCtD
Nafarelin—Vomiting—Irinotecan—stomach cancer	0.00109	0.00126	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—stomach cancer	0.00108	0.00126	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—ADRB1—stomach cancer	0.00108	0.0079	CbGpPWpGaD
Nafarelin—Dizziness—Fluorouracil—stomach cancer	0.00108	0.00125	CcSEcCtD
Nafarelin—Rash—Irinotecan—stomach cancer	0.00108	0.00125	CcSEcCtD
Nafarelin—Dermatitis—Irinotecan—stomach cancer	0.00108	0.00125	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Docetaxel—stomach cancer	0.00108	0.00125	CcSEcCtD
Nafarelin—Headache—Irinotecan—stomach cancer	0.00107	0.00124	CcSEcCtD
Nafarelin—Insomnia—Docetaxel—stomach cancer	0.00107	0.00124	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—HRH4—stomach cancer	0.00106	0.00775	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—stomach cancer	0.00106	0.00775	CbGpPWpGaD
Nafarelin—Paraesthesia—Docetaxel—stomach cancer	0.00106	0.00123	CcSEcCtD
Nafarelin—Alopecia—Methotrexate—stomach cancer	0.00106	0.00123	CcSEcCtD
Nafarelin—Dyspnoea—Docetaxel—stomach cancer	0.00105	0.00122	CcSEcCtD
Nafarelin—Mental disorder—Methotrexate—stomach cancer	0.00105	0.00122	CcSEcCtD
Nafarelin—Malnutrition—Methotrexate—stomach cancer	0.00104	0.00121	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—KISS1—stomach cancer	0.00104	0.00761	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Capecitabine—stomach cancer	0.00104	0.00121	CcSEcCtD
Nafarelin—Vomiting—Fluorouracil—stomach cancer	0.00104	0.00121	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—stomach cancer	0.00104	0.00121	CcSEcCtD
Nafarelin—Insomnia—Capecitabine—stomach cancer	0.00103	0.0012	CcSEcCtD
Nafarelin—Rash—Fluorouracil—stomach cancer	0.00103	0.0012	CcSEcCtD
Nafarelin—Dermatitis—Fluorouracil—stomach cancer	0.00103	0.0012	CcSEcCtD
Nafarelin—Paraesthesia—Capecitabine—stomach cancer	0.00103	0.00119	CcSEcCtD
Nafarelin—Decreased appetite—Docetaxel—stomach cancer	0.00103	0.00119	CcSEcCtD
Nafarelin—Headache—Fluorouracil—stomach cancer	0.00103	0.00119	CcSEcCtD
Nafarelin—Dysgeusia—Methotrexate—stomach cancer	0.00102	0.00118	CcSEcCtD
Nafarelin—Dyspnoea—Capecitabine—stomach cancer	0.00102	0.00118	CcSEcCtD
Nafarelin—Nausea—Irinotecan—stomach cancer	0.00102	0.00118	CcSEcCtD
Nafarelin—Constipation—Docetaxel—stomach cancer	0.00101	0.00117	CcSEcCtD
Nafarelin—Decreased appetite—Capecitabine—stomach cancer	0.000995	0.00115	CcSEcCtD
Nafarelin—Alopecia—Epirubicin—stomach cancer	0.000991	0.00115	CcSEcCtD
Nafarelin—Mental disorder—Epirubicin—stomach cancer	0.000983	0.00114	CcSEcCtD
Nafarelin—Constipation—Capecitabine—stomach cancer	0.000978	0.00113	CcSEcCtD
Nafarelin—Malnutrition—Epirubicin—stomach cancer	0.000977	0.00113	CcSEcCtD
Nafarelin—Nausea—Fluorouracil—stomach cancer	0.000972	0.00113	CcSEcCtD
Nafarelin—Tension—Epirubicin—stomach cancer	0.000958	0.00111	CcSEcCtD
Nafarelin—Dysgeusia—Epirubicin—stomach cancer	0.000956	0.00111	CcSEcCtD
Nafarelin—Nervousness—Epirubicin—stomach cancer	0.000948	0.0011	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—stomach cancer	0.000948	0.00691	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—KISS1—stomach cancer	0.000947	0.00691	CbGpPWpGaD
Nafarelin—Vertigo—Methotrexate—stomach cancer	0.000938	0.00109	CcSEcCtD
Nafarelin—Alopecia—Doxorubicin—stomach cancer	0.000917	0.00106	CcSEcCtD
Nafarelin—Mental disorder—Doxorubicin—stomach cancer	0.000909	0.00105	CcSEcCtD
Nafarelin—Urticaria—Capecitabine—stomach cancer	0.000909	0.00105	CcSEcCtD
Nafarelin—Convulsion—Methotrexate—stomach cancer	0.000904	0.00105	CcSEcCtD
Nafarelin—Malnutrition—Doxorubicin—stomach cancer	0.000904	0.00105	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—RGS2—stomach cancer	0.000897	0.00654	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GAST—stomach cancer	0.000897	0.00654	CbGpPWpGaD
Nafarelin—Chest pain—Methotrexate—stomach cancer	0.000888	0.00103	CcSEcCtD
Nafarelin—Arthralgia—Methotrexate—stomach cancer	0.000888	0.00103	CcSEcCtD
Nafarelin—Myalgia—Methotrexate—stomach cancer	0.000888	0.00103	CcSEcCtD
Nafarelin—Tension—Doxorubicin—stomach cancer	0.000887	0.00103	CcSEcCtD
Nafarelin—Dysgeusia—Doxorubicin—stomach cancer	0.000885	0.00103	CcSEcCtD
Nafarelin—Nervousness—Doxorubicin—stomach cancer	0.000878	0.00102	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—ADRB2—stomach cancer	0.000878	0.0064	CbGpPWpGaD
Nafarelin—Vertigo—Epirubicin—stomach cancer	0.000877	0.00102	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—KISS1R—stomach cancer	0.000868	0.00633	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GLI3—stomach cancer	0.000868	0.00633	CbGpPWpGaD
Nafarelin—Palpitations—Epirubicin—stomach cancer	0.000863	0.001	CcSEcCtD
Nafarelin—Asthenia—Docetaxel—stomach cancer	0.000848	0.000983	CcSEcCtD
Nafarelin—Convulsion—Epirubicin—stomach cancer	0.000846	0.000981	CcSEcCtD
Nafarelin—Pruritus—Docetaxel—stomach cancer	0.000836	0.000969	CcSEcCtD
Nafarelin—Chest pain—Epirubicin—stomach cancer	0.000831	0.000964	CcSEcCtD
Nafarelin—Myalgia—Epirubicin—stomach cancer	0.000831	0.000964	CcSEcCtD
Nafarelin—Arthralgia—Epirubicin—stomach cancer	0.000831	0.000964	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—RBP1—stomach cancer	0.000828	0.00604	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Methotrexate—stomach cancer	0.000823	0.000954	CcSEcCtD
Nafarelin—Asthenia—Capecitabine—stomach cancer	0.000821	0.000951	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—GAST—stomach cancer	0.000815	0.00594	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RGS2—stomach cancer	0.000815	0.00594	CbGpPWpGaD
Nafarelin—Vertigo—Doxorubicin—stomach cancer	0.000812	0.000941	CcSEcCtD
Nafarelin—Anorexia—Methotrexate—stomach cancer	0.000812	0.000941	CcSEcCtD
Nafarelin—Pruritus—Capecitabine—stomach cancer	0.000809	0.000938	CcSEcCtD
Nafarelin—Diarrhoea—Docetaxel—stomach cancer	0.000808	0.000937	CcSEcCtD
Nafarelin—Palpitations—Doxorubicin—stomach cancer	0.000799	0.000925	CcSEcCtD
Nafarelin—Oedema—Epirubicin—stomach cancer	0.000797	0.000924	CcSEcCtD
Nafarelin—Shock—Epirubicin—stomach cancer	0.000784	0.000909	CcSEcCtD
Nafarelin—Convulsion—Doxorubicin—stomach cancer	0.000783	0.000907	CcSEcCtD
Nafarelin—Diarrhoea—Capecitabine—stomach cancer	0.000783	0.000907	CcSEcCtD
Nafarelin—Dizziness—Docetaxel—stomach cancer	0.000781	0.000906	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Methotrexate—stomach cancer	0.000776	0.000899	CcSEcCtD
Nafarelin—Hyperhidrosis—Epirubicin—stomach cancer	0.00077	0.000893	CcSEcCtD
Nafarelin—Insomnia—Methotrexate—stomach cancer	0.00077	0.000893	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—stomach cancer	0.000769	0.000892	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—stomach cancer	0.000769	0.000892	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—stomach cancer	0.000769	0.000892	CcSEcCtD
Nafarelin—Paraesthesia—Methotrexate—stomach cancer	0.000765	0.000886	CcSEcCtD
Nafarelin—Anorexia—Epirubicin—stomach cancer	0.00076	0.00088	CcSEcCtD
Nafarelin—Dyspnoea—Methotrexate—stomach cancer	0.000759	0.00088	CcSEcCtD
Nafarelin—Dizziness—Capecitabine—stomach cancer	0.000757	0.000877	CcSEcCtD
Nafarelin—Vomiting—Docetaxel—stomach cancer	0.000751	0.000871	CcSEcCtD
Nafarelin—Rash—Docetaxel—stomach cancer	0.000745	0.000863	CcSEcCtD
Nafarelin—Dermatitis—Docetaxel—stomach cancer	0.000744	0.000863	CcSEcCtD
Nafarelin—Decreased appetite—Methotrexate—stomach cancer	0.00074	0.000858	CcSEcCtD
Nafarelin—Headache—Docetaxel—stomach cancer	0.00074	0.000858	CcSEcCtD
Nafarelin—Oedema—Doxorubicin—stomach cancer	0.000737	0.000855	CcSEcCtD
Nafarelin—Vomiting—Capecitabine—stomach cancer	0.000727	0.000843	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Epirubicin—stomach cancer	0.000726	0.000842	CcSEcCtD
Nafarelin—Shock—Doxorubicin—stomach cancer	0.000726	0.000841	CcSEcCtD
Nafarelin—Rash—Capecitabine—stomach cancer	0.000721	0.000836	CcSEcCtD
Nafarelin—Insomnia—Epirubicin—stomach cancer	0.000721	0.000835	CcSEcCtD
Nafarelin—Dermatitis—Capecitabine—stomach cancer	0.000721	0.000835	CcSEcCtD
Nafarelin—Headache—Capecitabine—stomach cancer	0.000717	0.000831	CcSEcCtD
Nafarelin—Paraesthesia—Epirubicin—stomach cancer	0.000716	0.000829	CcSEcCtD
Nafarelin—Hyperhidrosis—Doxorubicin—stomach cancer	0.000713	0.000826	CcSEcCtD
Nafarelin—Dyspnoea—Epirubicin—stomach cancer	0.000711	0.000824	CcSEcCtD
Nafarelin—Anorexia—Doxorubicin—stomach cancer	0.000703	0.000815	CcSEcCtD
Nafarelin—Nausea—Docetaxel—stomach cancer	0.000702	0.000813	CcSEcCtD
Nafarelin—Decreased appetite—Epirubicin—stomach cancer	0.000693	0.000803	CcSEcCtD
Nafarelin—Constipation—Epirubicin—stomach cancer	0.000682	0.00079	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—AGTR2—stomach cancer	0.00068	0.00496	CbGpPWpGaD
Nafarelin—Nausea—Capecitabine—stomach cancer	0.00068	0.000788	CcSEcCtD
Nafarelin—Urticaria—Methotrexate—stomach cancer	0.000677	0.000784	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—WWOX—stomach cancer	0.000675	0.00492	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—F2R—stomach cancer	0.000672	0.0049	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—stomach cancer	0.000672	0.000779	CcSEcCtD
Nafarelin—Insomnia—Doxorubicin—stomach cancer	0.000667	0.000773	CcSEcCtD
Nafarelin—Paraesthesia—Doxorubicin—stomach cancer	0.000662	0.000767	CcSEcCtD
Nafarelin—Dyspnoea—Doxorubicin—stomach cancer	0.000657	0.000762	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—HTR1A—stomach cancer	0.000654	0.00477	CbGpPWpGaD
Nafarelin—Decreased appetite—Doxorubicin—stomach cancer	0.000641	0.000743	CcSEcCtD
Nafarelin—Urticaria—Epirubicin—stomach cancer	0.000633	0.000734	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—ANXA1—stomach cancer	0.000632	0.00461	CbGpPWpGaD
Nafarelin—Constipation—Doxorubicin—stomach cancer	0.000631	0.000731	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HRH4—stomach cancer	0.000628	0.00458	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—WIF1—stomach cancer	0.000628	0.00458	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AGTR2—stomach cancer	0.000617	0.0045	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ADRB1—stomach cancer	0.000612	0.00446	CbGpPWpGaD
Nafarelin—Asthenia—Methotrexate—stomach cancer	0.000611	0.000708	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—F2R—stomach cancer	0.00061	0.00445	CbGpPWpGaD
Nafarelin—Pruritus—Methotrexate—stomach cancer	0.000603	0.000698	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—HTR1A—stomach cancer	0.000594	0.00433	CbGpPWpGaD
Nafarelin—Urticaria—Doxorubicin—stomach cancer	0.000586	0.000679	CcSEcCtD
Nafarelin—Diarrhoea—Methotrexate—stomach cancer	0.000583	0.000675	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PRKAB1—stomach cancer	0.000579	0.00422	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—stomach cancer	0.000578	0.00421	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ANXA1—stomach cancer	0.000574	0.00418	CbGpPWpGaD
Nafarelin—Asthenia—Epirubicin—stomach cancer	0.000572	0.000663	CcSEcCtD
Nafarelin—Pruritus—Epirubicin—stomach cancer	0.000564	0.000654	CcSEcCtD
Nafarelin—Dizziness—Methotrexate—stomach cancer	0.000563	0.000653	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—KISS1—stomach cancer	0.00056	0.00408	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RNF43—stomach cancer	0.00056	0.00408	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	0.000557	0.00406	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ADRB1—stomach cancer	0.000556	0.00405	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—stomach cancer	0.00055	0.00401	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—stomach cancer	0.000549	0.00401	CbGpPWpGaD
Nafarelin—Diarrhoea—Epirubicin—stomach cancer	0.000545	0.000632	CcSEcCtD
Nafarelin—Vomiting—Methotrexate—stomach cancer	0.000541	0.000628	CcSEcCtD
Nafarelin—Rash—Methotrexate—stomach cancer	0.000537	0.000622	CcSEcCtD
Nafarelin—Dermatitis—Methotrexate—stomach cancer	0.000536	0.000622	CcSEcCtD
Nafarelin—Headache—Methotrexate—stomach cancer	0.000534	0.000618	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3CA—stomach cancer	0.000533	0.00389	CbGpPWpGaD
Nafarelin—Asthenia—Doxorubicin—stomach cancer	0.000529	0.000613	CcSEcCtD
Nafarelin—Dizziness—Epirubicin—stomach cancer	0.000527	0.000611	CcSEcCtD
Nafarelin—Pruritus—Doxorubicin—stomach cancer	0.000522	0.000605	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—stomach cancer	0.000519	0.00378	CbGpPWpGaD
Nafarelin—Vomiting—Epirubicin—stomach cancer	0.000507	0.000587	CcSEcCtD
Nafarelin—Nausea—Methotrexate—stomach cancer	0.000506	0.000586	CcSEcCtD
Nafarelin—Diarrhoea—Doxorubicin—stomach cancer	0.000505	0.000585	CcSEcCtD
Nafarelin—Rash—Epirubicin—stomach cancer	0.000503	0.000582	CcSEcCtD
Nafarelin—Dermatitis—Epirubicin—stomach cancer	0.000502	0.000582	CcSEcCtD
Nafarelin—Headache—Epirubicin—stomach cancer	0.000499	0.000579	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FST—stomach cancer	0.000499	0.00364	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ADRB2—stomach cancer	0.000496	0.00362	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HBEGF—stomach cancer	0.000488	0.00356	CbGpPWpGaD
Nafarelin—Dizziness—Doxorubicin—stomach cancer	0.000488	0.000565	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—RGS2—stomach cancer	0.000481	0.00351	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GAST—stomach cancer	0.000481	0.00351	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—stomach cancer	0.000477	0.00348	CbGpPWpGaD
Nafarelin—Nausea—Epirubicin—stomach cancer	0.000473	0.000549	CcSEcCtD
Nafarelin—Vomiting—Doxorubicin—stomach cancer	0.000469	0.000543	CcSEcCtD
Nafarelin—Rash—Doxorubicin—stomach cancer	0.000465	0.000539	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—stomach cancer	0.000465	0.000538	CcSEcCtD
Nafarelin—Headache—Doxorubicin—stomach cancer	0.000462	0.000535	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—FGG—stomach cancer	0.000456	0.00333	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ADRB2—stomach cancer	0.00045	0.00328	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PPP2R1A—stomach cancer	0.000441	0.00322	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—stomach cancer	0.000441	0.00322	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRKAA1—stomach cancer	0.000439	0.0032	CbGpPWpGaD
Nafarelin—Nausea—Doxorubicin—stomach cancer	0.000438	0.000508	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—RBP4—stomach cancer	0.000424	0.00309	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL8—stomach cancer	0.000424	0.00309	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	0.000422	0.00308	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AGTR2—stomach cancer	0.000365	0.00266	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HSPB1—stomach cancer	0.000365	0.00266	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—F2R—stomach cancer	0.000361	0.00263	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BMP2—stomach cancer	0.000361	0.00263	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKR1C3—stomach cancer	0.000355	0.00259	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HTR1A—stomach cancer	0.000351	0.00256	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PRKCB—stomach cancer	0.00034	0.00248	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ANXA1—stomach cancer	0.000339	0.00247	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ADRB1—stomach cancer	0.000328	0.00239	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RPS6—stomach cancer	0.000314	0.00229	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PRKCB—stomach cancer	0.000309	0.00225	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6ST—stomach cancer	0.000307	0.00224	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HBEGF—stomach cancer	0.000288	0.0021	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6R—stomach cancer	0.000274	0.002	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—RHOA—stomach cancer	0.000273	0.00199	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ADRB2—stomach cancer	0.000266	0.00194	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PPP2R1A—stomach cancer	0.000261	0.0019	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RHOA—stomach cancer	0.000248	0.00181	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SMAD4—stomach cancer	0.000242	0.00176	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL8—stomach cancer	0.00024	0.00175	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FYN—stomach cancer	0.00023	0.00168	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL8—stomach cancer	0.000218	0.00159	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGFR2—stomach cancer	0.000216	0.00157	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IRS2—stomach cancer	0.000198	0.00144	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CAV1—stomach cancer	0.000192	0.0014	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOA1—stomach cancer	0.000191	0.00139	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PRKCB—stomach cancer	0.000182	0.00133	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6ST—stomach cancer	0.000182	0.00132	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APC—stomach cancer	0.000175	0.00127	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAPK3—stomach cancer	0.000167	0.00122	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6R—stomach cancer	0.000162	0.00118	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAPK1—stomach cancer	0.000159	0.00116	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EGFR—stomach cancer	0.000159	0.00116	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CA—stomach cancer	0.000152	0.00111	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SERPINE1—stomach cancer	0.000152	0.00111	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—stomach cancer	0.00015	0.00109	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RHOA—stomach cancer	0.000146	0.00107	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOS3—stomach cancer	0.000145	0.00106	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CA—stomach cancer	0.000138	0.00101	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ERBB2—stomach cancer	0.000135	0.000988	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL8—stomach cancer	0.000128	0.000937	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HRAS—stomach cancer	0.000128	0.000931	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1B—stomach cancer	0.000125	0.000915	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—stomach cancer	0.000122	0.000891	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—stomach cancer	0.00012	0.000873	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JUN—stomach cancer	0.000119	0.000871	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—stomach cancer	0.000116	0.000847	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1A—stomach cancer	0.000116	0.000844	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK8—stomach cancer	0.000113	0.000824	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—stomach cancer	0.000104	0.000761	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—stomach cancer	0.000103	0.000753	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK3—stomach cancer	9.87e-05	0.00072	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—stomach cancer	9.6e-05	0.0007	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK1—stomach cancer	9.39e-05	0.000685	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGFR—stomach cancer	9.39e-05	0.000685	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—stomach cancer	8.87e-05	0.000647	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CA—stomach cancer	8.15e-05	0.000594	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—stomach cancer	7.89e-05	0.000575	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRAS—stomach cancer	7.54e-05	0.00055	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—stomach cancer	7.22e-05	0.000526	CbGpPWpGaD
